Drug Approval | October 07, 2023
Lupin receives tentative approval from USFDA for Tolvaptan Tablets
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed- Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
The company has received six final approvals that includes Chlorpromazine Hydrochloride Tablets
India has the highest prevalence of diabetes globally, with an estimated 77 million people living with the condition and an expected 134 million cases by 2045
Dr. Karikó is the third Solvay Prize winner to become a Nobel Prize laureate
SigTuple’s AI100 with Shonit is the premier solution for AI assisted digital pathology
Diofan Ultra736 provides ultra-high water vapor barrier with excellent thermoformability, unlocking the potential to design thinner and more sustainable blister films
The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
